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Abstract
Background: Azelnidipine (AZL), a long-acting dihydropyridine-based calcium antagonist, has been recently
approved and used for treating ischemic heart disease and cardiac remodeling after myocardial infarction,
however, its effect on hyperglycemia-induced cardiac damage has not been studied.
Methods: This study examined the effect of AZL on circulating markers of cardiac damage, altered lipid and
cytokines profile and markers of oxidative stress including homocysteine in diabetic rats.
Results: STZ induced diabetes caused a significant increase in blood glucose levels. It also resulted in an increase
in the levels of homocysteine and cardiac damage markers, like Troponin-1, CK-MB, CK-NAC, uric acid, LDH and
alkaline phosphatase. Moreover, there was an increase in the levels of proinflammatory cytokines like TNF-a, IFN-g,
and TGF-b and decrease in the levels of IL-4 and IL-10. Additionally, there was increase in the levels of cholesterol,
triglycerides, LDL, VLDL and a decrease in HDL in these animals. There was an altered antioxidant enzyme profile
which resulted in a notable increase in the levels of oxidative stress markers like lipid peroxides, nitric oxide and
carbonylated proteins. Compared with the untreated diabetic rats, AZL treatment significantly reduced the levels of
troponin-1 (P < 0.05), CK-MB (P < 0.05), CK-NAC (P < 0.05), uric acid (P < 0.05), LDH (P < 0.05) and alkaline
phosphatase (P < 0.05). It also reduced the levels of the TNF-a (P < 0.05), IFN-g (P < 0.05), and TGF-b (P < 0.05)
and increased the levels of IL-4 (P < 0.05). A significant decrease in the serum cholesterol (P < 0.05), triglycerides
(P < 0.05), LDL (P < 0.05), VLDL (P < 0.05) and a significant rise in levels of HDL (P < 0.05) was also observed.
Treatment with AZL corrected the distorted antioxidant enzyme profile resulting in a significant decrease in the
levels of lipid peroxides, nitric oxide and carbonylated proteins.
Conclusion: Our results indicate that AZL treatment can reduce the risk of hyperglycemia induced metabolic
disorders and its role can be further extended to explore its therapeutic potential in diabetic patients with cardiac
complications.
Background
Improper management of metabolic disturbances espe-
cially altered lipid and protein metabolism in diabetes
results in grave cardiovascular complications which
causes increasing diabetes-related mortalities [1]. Dysli-
pidemia, oxidative stress and inflammatory injury are
important interrelated factors responsible for the devel-
opment of cardiomyopathy as they are known to pro-
mote the progression of premature atherosclerosis,
coronary insufficiency and myocardial infarction [2].
Various studies have correlated that the circulating
markers of myocardial damage, pro-inflammatory cyto-
kines, calcium dysregulation, oxidative stress and athero-
genic lipids are elevated in diabetic patients [3-10].
Metabolically, the diabetic heart is characterized by
diminished glucose utilization and increased fatty acid
oxidation resulting in lipid accumulation in the myocar-
dium [11,12]. This myocardial lipotoxicity results in
alterations in the inflammatory cytokines levels and
evokes a cascade of disparaging changes that leads to
cardiac damage. Recently, proinflammatory cytokines
like TNF-a and IFN-g have been shown to alter the cal-
cium regulation and directly or indirectly reduce the
myocardial contractility [13-18]. Likewise, the proinflam-
matory and profibrotic cytokine, TGF-b contributes to
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cardiac muscle L-type calcium current and charge
movement [19,20]. These cytokine-induced cascades of
events mechanistically contribute to cardiomyocyte
apoptosis possibly due to disturbance of calcium home-
ostasis via redox regulatory mechanisms leading to
extensive myocyte cell death.
There is an alteration in the antioxidant enzyme levels
which leads to oxidative stress as the production of
reactive oxygen species (ROS) exceeds its scavenging.
Oxidative stress directly leads to lipid peroxidation, pro-
tein carbonylation and cardiac fibrosis significantly con-
tributing to pathophysiology of cardiac complications of
diabetes [21-25]. It has been shown that increased cal-
cium flux further aggravates oxidative stress and vice
versa [26-29]. Thus the role of calcium channel blockers
(CCBs) becomes extremely important for correcting this
underlying phenomenon.
CCBs initially used to treat hypertension found addi-
tional beneficial implications in various conditions, such
as angina pectoris, hypertrophic cardiomyopathy, pul-
monary hypertension and diabetic cardiomyopathy [30].
There are 3 main classes–phenylalkylamines, benzothia-
zepines, and dihydropyridines (DHP) because of differ-
ence in their molecular structure, sites and modes of
action, and effects on various other cardiovascular func-
tions [31]. Primarily, the CCBs lower blood pressure
through vasodilation and reduction of peripheral resis-
tance and usually do not impair glucose metabolism or
lipid profile and may even attenuate the development of
arteriosclerotic lesions [30]. Inferring from these studies,
it seems that calcium antagonists are also safe and effec-
tive as first-line or add-on therapy in diabetic hyperten-
sive patients [32]. Thus, CCBs with lipid-lowering, anti-
oxidative and/or anti-inflammatory activities may poten-
tially prevent or delay the occurrence of diabetic
cardiomyopathy.
AZL, a newly developed and commercially used novel
long-acting DHP-based calcium antagonist has been
reported to be effective in treating ischemic heart dis-
ease and cardiac remodeling after myocardial infarction
(MI) [3] and reduce blood pressure without increasing
the heart rate in patients with hypertension [33,34]. In
the experimental animals, AZL revealed anti-athero-
sclerotic effects independent of its blood pressure-lower-
ing actions [35]. In another study, AZL prevented the
TNF-induced endothelial cell activation via its antioxida-
tive properties [36]. AZL also inhibited H2O2-induced
cell death in neonatal rat cardiomyocytes [37]. However,
the effects of AZL on diabetes induced cardiac damage
have not been studied.
In the light of the above findings, we chose to investi-
gate the possible effect of AZL on the circulating
markers of cardiac damage (troponin 1, CK-MB,
CK-NAC, LDH, uric acid), oxidative stress (lipid perox-
ides, nitric oxide, carbonyl content), antioxidant enzyme
(superoxide dismutase, catalase and reduced glu-
tathione), serum hcy, proinflammatory and anti-inflam-
matory cytokines (TNF-a,I F N - g,T G F - b,I L - 4a n dI L -
10) and atherogenic lipid profile in STZ induced dia-
betic rats.
Methods
Six to eight-week-old male Wistar rats (NCCS, Pune,
India) weighing 300 to 330 g were made diabetic by a
single intraperitoneal injection of streptozotocin (STZ)
(55 mg/kg, Sigma, St. Louis, MO) as described pre-
viously [23]. Control animals were treated with vehicle
(0.1 mol/L sodium citrate buffer, pH 4.5). Hyperglyce-
mia (blood glucose > 200 mg/dL) was confirmed 3 days
post STZ injection using a glucometer (AccuCheck;
Roche, Germany). Diabetic animals were treated with
AZL suspended in 1% carboxy methyl cellulose at a sin-
gle daily dose of 5 mg/kg, administered orally by gavage
on the 4
th day of STZ treatment (n = 12) for 12 weeks.
At the end of the study duration, rats were fasted over-
night, anesthetized using 500 mg/kg dose of urethane
and the blood was collected via heart puncture with a
19½ gauge needle. The animals were then euthanized by
cervical dislocation. Urethane was selected in the pre-
sent study as an anesthetic agent as a single dose
induces long term anesthesia with minimal cardiovascu-
lar and respiratory system depression. It is a convenient
one shot method for non-recovery studies and produces
a level of surgical anesthesia and analgesia characterized
by preservation of a number of cardiovascular reflexes
[38]. All procedures were approved by Institutional Ani-
mal Care and Use Committee and complied with stan-
dards for the care and use of animal subjects, as stated
in the Guide for the Care and Use of Laboratory Ani-
mals (Institute of Laboratory Resources, National Acad-
emy of Sciences, Bethesda, MD).
Heart was excised and the heart weight (HW) and left
ventricular mass (LVM) was noted.
For the isolation of plasma, the blood was collected in
EDTA-coated Vacutainer (BD Vacutainer®, USA) was
isolated after centrifuging blood in a pre-cooled centri-
fuge at 1500 rpm for 10 min at 1500 × g. For isolation
of serum, the blood was allowed to clot at room tem-
perature for 15 to 20 minutes then centrifuged for 10
minutes at 1000 × g.
Serum Insulin
Serum insulin levels were measured by the High-range
Rat Insulin ELISA kit from Mercodia AB, (Sweden) as
per manufacturer’s instructions [39].
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Performance Liquid Chromatography (HPLC)
Serum hcy was analyzed by HPLC as described pre-
viously [40]. The HPLC system (Dionex, Germany) con-
sisted of P-680 quaternary gradient pump, an ASI 100
autosampler, a universal chromatographic interface
UCI-50 and fluorescence detector RF-2000 integrated by
Chromeleon Software 6.70 coupled to pH stable reverse
phase C18 column (4.6 × 250 mm, Varian, Varian Inc).
Thiol-specific fluorogenic reagent 4-(aminosulfonyl)-7-
fluoro-2,1,3-benzoxadiazole (ABD-F) was used as fluro-
chrome. Mobile phase used was ammonium phosphate
buffer (0.01 M) and acetonitrile (80:20) with flow rate as
0.5 mL per min. The limit of detection of hcy (Sigma
Inc, USA) was 500 nmol L
-1.
Cytokines assay
TNF-a,I F N - g,T G F - b,I L - 4a n dI L - 1 0i nt h ep l a s m a
were determined by the sandwich ELISA method using
a commercially available kit from BD OptEIA ELISA Set
(BD Biosciences, USA) as per manufacturer’si n s t r u c -
tions. The data are expressed as picogram per milliliter.
For each assay the cytokine standards were used each
time to check the variation from plate to plate on differ-
ent days of analyses.
Biochemical Markers of Myocardial Injury in serum
Estimation of total cholesterol, low density lipoprotein,
high density lipoproteins, very low density lipoproteins,
creatine kinase (CK-MB and CK-NAC), lactate dehydro-
genase (LDH), uric acid and troponin I in the serum
was done using appropriate kits on RA-50 semi auto
analyzer by well standardized methods.
Liver function tests
Quantitative estimation of Alanine aminotranferease
(ALT), aspartate aminotransferase (AST) and alkaline
phosphatase was done using sp e c i f i ck i t[ E r b aD i a g n o s -
tics Mannheim GmBH, Germany] using RA -50 semi
auto analyzer by well standardized methods [41].
Mesurement of lipid peroxidation
Determination of lipid peroxidation (nmole malondial-
dehyde/mg protein) was done spectrophotometrically
using the thiobarbituric acid-reactive substance
(TBARS) by the method of Uchiyama and Mihara [42]
using 1,1,3,3-tetramethoxypropane as a standard.
Estimation of antioxidant enzyme levels
The level of SOD and catalase enzyme activities was
measured using the SOD Assay Kit-WST and Catalase
Assay kit (Sigma, St. Louis, MO) according to the man-
ufacturer’s instructions. The concentration of reduced
glutathione (GSH) was determined according to Ellman
[43]. All assays were performed in triplicate and on the
same day to reduce inter-assay variation. Activities were
normalized to protein in the sample using previously
described spectrophotometric dye binding methods
[44].
Estimation of Nitrite oxide
Nitric oxide was quantitated by using Griess Reagent Kit
for Nitrite Determination (Molecular Probes, USA) as
per manufacturer’s instructions.
Protein carbonyl assay
The level of protein carbonyl groups was estimated
according to the method of Levine et al. [45] with slight
modifications. Briefly, the samples were incubated with
2,4-dinitrophenylhydrazine (DNPH) for 1 h followed by
precipitation with trichloroacetic acid. After centrifuga-
tion, the pellets were washed with an ethanol-ethyl acet-
ate mixture to remove the excess DNPH, dissolved in
guanidine hydrochloride solution (6 mol/L) and the
absorbance was measured at 370 nm. The content of
carbonyl groups was calculated using the molar extinc-
tion coefficient of 22,000 (l/cm mol). The content of
protein was assayed by the method of Lowry et al [46],
using bovine serum albumin as standard.
Statistical analysis
Data are expressed as means ± standard error (SE) and
were analyzed using one-way analysis of variance and
secondary analysis for significance with Tukey-Kramer
post tests using Prism 4.0 GraphPad software (Graph-
Pad, San Diego,C A ,U S A ) .Ap value less than 0.05 was
considered statistically significant.
Results
Characterization of animal groups
Animals in the untreated STZ diabetic group displayed
severe hyperglycemia, significant decrease in the levels
of insulin and an increase in the LVM/BW ratio (as an
index of ventricular hypertrophy). AZL treatment
reduced the glucose levels although the levels remained
elevated than the controls. AZL treatment also improved
the levels of serum insulin. AZL treatment resulted in a
significant decrease in the LVM/BW ratio indicating
that AZL treatment prevents left ventricular hypertro-
phy. The data for blood glucose, serum insulin, and
LVM/BW ratio has been tabulated in Table 1. There
was also a notable increase in the levels of total serum
cholesterol, triglycerides, LDLs and VLDL. Levels of
HDL decreased in the STZ-diabetic rats there by signifi-
cantly increasing the total cholesterol to HDL ratio and
HDL to LDL ratio.
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Hcy concentration in blood has been predicted as a
powerful prognostic marker of cardiac complications of
diabetes [47]. STZ diabetic rat showed a significant
increase in the levels of hcy which were significantly
reduced after AZL treatment (Table 1).
AZL treatment reduces the markers of cardiac damage
Compared to the controls, the circulating markers of
cardiac damage in STZ diabetic rat, showed a significant
increase in the levels of serum troponin I (1.21 ± 0.13
ng/mL vs. 0.72 ± 0.15 ng/mL), CK-MB (135.0 ± 29.5
IU/L vs. 37.50 ± 9.9 IU/L) and CK-NAC (1013.0 ± 96.3
IU/L vs. 81.21 ± 32.43 IU/L), LDH (407.0 ± 64.72 IU/L
vs. 95.0 ± 10.99 IU/L) and uric acid (8.53 ± 1.54 mg/dL
vs. 3.93 ± 0.5 mg/dL). This notable increase was signifi-
cantly reduced by AZL treatment. The levels of troponin
I (0.66 ± 0.08 ng/mL), CK-MB (38.8 ± 4.0 IU/L), and
CK-NAC (150.32 ± 61.2 IU/L), LDH (61.50 ± 21.0 IU/
L), Uric acid (2.1 ± 0.93 mg/dl) and alkaline phospha-
tase (149.6 ± 8.43 IU/L) were significantly lower when
compared with the STZ diabetic group (Figure 1).
Improvement of proinflammatory cytokines after AZL
treatment
Compared to the controls, STZ diabetic rat demonstrated
significantly increased levels of the pro-inflammatory cyto-
kines TNF-a (389.1 ± 46.2 pg/mL vs. 81.6 ± 28.3 pg/mL),
IFN-g (299.3 ± 42.9 pg/mL vs. 149.6 ± 17.6 pg/mL), TGF-
b (2875.3 ± 349.08 pg/mL vs. 1913.3 ± 362.1 pg/mL).
There was a notable decrease in levels of IL-4 (63.8 ± 11.1
pg/mL vs. 105.9 ± 24.2 pg/mL) and IL-10 (462.4 ± 31.2
pg/mL vs. 979.5 ± 150.3 pg/mL). AZL treatment prevented
t h ei n c r e a s ei nt h el e v e l so fT N F - a (90.0 ± 14.8 pg/mL),
IFN-g (200.2 ± 38.1 pg/mL), and TGF-b (1892.4 ± 321.0
pg/mL). It also resulted in an increase in the levels of IL-4
(132.1 ± 22.9 pg/mL), which was even higher than the
controls (Figure 2). However, levels of IL-10 remained
unchanged (499.2 ± 110.5 pg/mL) in AZL treatment
group when compared to STZ diabetic group.
Normalization of altered lipid profile after AZL treatment
AZL had a significant effect on lowering triglyceride,
cholesterol, LDL and VLDL levels and increasing HDL
levels in diabetic rats (Table 2A). Diabetic rats treated
with AZL also showed significant decreases in total cho-
lesterol and total cholesterol/HDL ratio, as well as ele-
vated levels of HDL cholesterol (Table 2B). All these
levels were completely normalized after AZL treatment
which suggests that AZL is far more effective in main-
taining the lipid profile near to that of control in this
animal model of diabetes.
Effect of AZL on the markers of liver function
Diabetes was found to increase the levels of the liver
marker enzymes ALT (60.7 ± 8.8), AST (86.7 ± 10.5)
and alkaline phosphatase (330.0 ± 12.51 IU/L) compared
with those of the controls viz. 37.5 ± 11.5, 27.7 ± 2.5
and 181.7 ± 32.9 IU/L, respectively. After treatment
with AZL, the levels of ALT, AST and alkaline phospha-
tase were observed to be normalized at 27.5 ± 5.2 for
ALT, 32.0 ± 4.0 for AST and 149.6 ± 8.4 IU/L for alka-
line phosphatase, indicatingt h a tA Z Lt r e a t m e n td o e s
not metabolically induce xenobiotic hepatotoxicity
(Figure 3).
Effect of AZL treatment on diabetes-Induced Oxidative
Stress
Lipid peroxides formation (nmol MDA/mg protein)
which is a direct marker for oxidative stress increased
significantly in the cardiac tissue of STZ group com-
pared with the control (STZ 14.5 ± 2.5 vs. control 2.1 ±
0.5, P < 0.05). AZL treatment significantly reduced the
levels of lipid peroxidation (3.2 ± 1.1, P < 0.05) which
was very close to the control group (Figure 4A). With
respect to the control group the levels of carbonyl con-
tent (nmol/mg protein), another indicator of oxidative
stress, were also increased in diabetic rat (STZ 44.2 ±
4.5 vs. control 7.7 ± 1.9, P < 0.05) and AZL treatment
significantly prevented this increase (10.2 ± 4.9, P <
0.05) (Figure 4B). Levels of nitric oxide, which is indica-
tive of nitrosative stress (μmol/L), increased signifi-
cantly in diabetic rat heart when compared to control
(STZ 259.3 ± 29.3 vs. control 21.3 ± 4.4, P <0 . 0 5 ) .T h i s
nitric oxide level after AZL treatment were reduced
(29.55 ± 11.3, P < 0.05) and were close to control group
(Figure 4C).
Table 1 Effect of AZL treatment on blood glucose, insulin, homocysteine and LVW/BW ratio in STZ-treated diabetic
rats
Parameters Control (n = 10) STZ* (n = 10) AZL (5 mg/kg/day)** (n = 10)
Blood Glucose (mg/dL) 167.5 ± 25.5 517.5 ± 45.5 256.2 ± 12.4
Serum Insulin (ng/mL) 3.3 ± 0.4 0.42 ± 0.3 1.40 ± 0.4
Homocysteine (μM/L) 2.9 ± 0.7 26.5 ± 4.4 13.8 ± 3.9
LVW/BW ratio (mg/g) 3.5 ± 0.12 4.9 ± 0.02 3.4 ± 0.43
Values are mean ± SE. * means p < 0.05 compared to control group, ** means p < 0.05 compared to STZ diabetic group.
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Page 4 of 9Figure 2 Effect of AZL treatment on plasma cytokine profile in
STZ-treated diabetic rats. (A) TNF a (B) IFN-g (C) TGF-b (D) IL-4 (E)
IL-10 levels. Values depict means ± SE for at least n = 8 animals in
each group. * means p < 0.001 compared to control group and **
means p < 0.01 compared to STZ diabetic group.
Table 2 (A) Effect of AZL treatment on serum lipid
profile. B) Atherogenic risk marker and cardiovascular
risk indicator
CTRL STZ AZL(5 mg/kg/day)
SERUM CHOLESTEROL
(mg/dL)
70.3 ± 6.4 165 ± 9.6* 71 ± 5.9
#
SERUM
TRIGLYCERIDES
(mg/dL)
68 ± 7.4 146 ± 12.5* 74 ± 11.3
#
HDL (mg/dL) 46 ± 3.5 29 ± 7.1* 48 ± 5.2
#
LDL (mg/dL) 34 ± 3.9 66 ± 7.9* 41 ± 5.0
#
VLDL (mg/dL) 13.6 ± 3 29.2 ± 5.5* 14.8 ± 5.1
#
Total Cholesterol/HDL 1.5 ± 0.2 5.6 ± 0.1* 1.4 ± 0.2
#
LDL/HDL 0.7 ± 0.1 2.2 ± 0.1* 0.8 ± 0.1
#
Values depict mean ± SE for at least n = 6 animals in each group. * means p
< 0.05 compared to control group and # means p < 0.05 compared to STZ
diabetic group.
Figure 1 Effect of AZL treatment on serum cardiac markers in STZ-treated diabetic rats (A) Troponin I (B) CK-MB (C) CK-NAC (D) LDH
(E) Uric acid levels. Values depict means ± SE for at least n = 8 animals in each group. * means p < 0.01 compared to control group and **
means p < 0.01 compared to STZ diabetic group
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Levels of SOD (U/mg protein) and GSH (ng/mg pro-
tein) were depressed significantly in the diabetic rat
(STZ 40 ± 0.8 vs. control 13.4 ± 2.2, P < 0.05 and GSH
57.9 ± 32.3 vs. control 493.5 ± 46.2, P <0 . 0 5 ) ,w h e r e a s
level of catalase (mU/mg protein) increased significantly
compared with controls (STZ 3955.6 ± 457.3 vs. control
1102.8 ± 304.3, P < 0.05). These different enzyme and
non-enzyme antioxidant levels were normalized after
AZL treatment (SOD 14.1 ± 2.0, P < 0.05; GSH 367.26
±3 1 . 1 ,P < 0.05 and catalase 996.65 ± 322.60, P <0 . 0 5 )
(Figure 4D-F).
Discussion
Diabetes is a metabolic syndrome with a cluster of com-
mon clinical disorders that is related with an increased
risk for cardiovascular disease [48]. Despite some con-
troversy in the past [49], large patient studies have
demonstrated that calcium channel blockers are effective
in reducing the mortality and morbidity of cardiovascu-
lar disease [50,51]. AZL is one of the cardiobeneficial
CCB that decreases blood pressure without increasing
the heart-rate [33,34], prevents cardiac damage [3],
reduce glucose intolerance [52] and possesses antioxi-
dant properties [37]. However, there is a significant gap
in our knowledge about the cardioprotective action and
efficacy of AZL as the effect of AZL on proinflammatory
cytokines and altered lipid profile in either diabetic
patients or in experimental models of diabetes has not
Figure 3 Effect of AZL treatment on liver function test (A) AST
(B) ALT (C) Alkaline phosphatase in serum of STZ-treated
diabetic rats. Values depict mean ± SE for at least n = 8 animals in
each group. * means p < 0.001 compared to control group and **
means p < 0.01 compared to STZ diabetic group.
Figure 4 Effect of AZL treatment on levels of oxidative stress markers and antioxidants. (A) Lipid peroxidation (B) Nitric oxide (C) Carbonyl
content (D) Superoxide dismutase (E) reduced glutathione (F) Catalase. Values are means ± SE of 6 rats. * means p < 0.001 compared to control
group, ** means p < 0.01 compared to STZ diabetic group.
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evaluated the effect of AZL on circulating markers of
cardiac damage secondary to diabetes.
Diabetic cardiomyopathy characterized by diastolic
dysfunction and left ventricular hypertrophy is usually
the terminal condition of heart in diabetes [53]. Our
results indicate that 12-week treatment of AZL in dia-
betic rats proved to be beneficial as it restrained the
progression of the metabolic disorders of diabetes. The
STZ diabetic rats showed elevated blood glucose levels
with reduced levels of serum insulin. Also, there was a
notable increase in the LVW/BW ratio which signifies
cardiac hypertrophy. AZL did not affect the serum insu-
lin levels indicating that it does not affect the function
of b-cells in the pancreas although there was a remark-
able improvement in the blood glucose levels. AZL has
been shown to improve glucose intolerance in the dia-
betic mice mainly through inhibition of oxidative stress
[52]. This improvement in the blood glucose levels
could be attributed to its ancillary properties partially
because of its lipid lowering capability and partially
because of its antioxidant nature. AZL treatment
showed a distinct positive effect on LVW/BW ratio indi-
cating that AZL was able to prevent cardiac hypertrophy
which usually sets in as a result of diastolic dysfunction
secondary to diabetes.
Elevated hcy level is also an independent risk factor
for the development of atherosclerosis as well as a prog-
nostic marker in ischemic heart disease [47,54]. Protein
homocysteinylation is a novel example of protein
damage that can be attributed to hyperhomocysteinemia
[55]. Homocysteinylated proteins were prone to multi-
merization and underwent gross structural changes that
led to their denaturation. Homocysteine thiolactone may
also inactivate enzymes responsible for posttranslational
modification of connective tissue matrices leading to
fibrosis and scarring [56]. Hcy also promotes atherogen-
esis through oxidative damage that is mediated by cyto-
toxic free radicals or by the induction of pro-
inflammatory factors [57]. Moreover, under the diabetic
condition, endogenously upregulated homocysteine
levels induce endothelial-myocyte uncoupling which
further aggravate the deteriorating condition of the
myocardium [58]. In our study, AZL treatment signifi-
cantly lowered the elevated Hcy levels indicating
that AZL can prevent accumulation of free radicals,
atherogenic plaque formation and reducing protein
homocysteinylation.
Diabetes is associated with an increase in the oxidative
stress that results from exhaustion of cellular antioxi-
dants and depletion of antioxidant enzymes [59]. The
results from our study showed that STZ induced dia-
betic condition resulted in an increase in the lipid per-
oxidation and protein carbonylation which are direct
indicators systemic oxidative stress. This was in con-
junction with depletion of superoxide scavenger SOD
and reduced glutathione along with an increase in the
levels of antioxidant enzyme catalase. AZL treatment in
the STZ-diabetic rats reduced the formation of lipid
peroxides, nitric oxides and carbonyl content and also
restored the levels of SOD and GSH. AZL also reduced
the levels of catalase indicating a reduction in the accu-
mulation of reactive oxygen species. This positive bene-
ficial effect of AZL could be directly attributable to its
antioxidative nature which is agreement with previous
findings [52,58].
It is widely accepted that high levels of circulating car-
diac damage markers like troponin I, CK-MB, CK-NAC,
LDH and uric acid represent a powerful and sensitive
predictor of increased cardiac complications [60]. In this
study, AZL-treated diabetic rats showed a significant
improvement in levels of these circulating cardiac damage
markers. This indicates that AZL prevents cardiac
damage and has beneficial properties far beyond its anti-
hypertensive actions. One of the possible mechanisms of
prevention may partially be related to suppression of
severe increase in the levels of pro-inflammatory cyto-
kines which was observed in STZ diabetic rats. Our
results were in agreement with previous reports where
AZL treatment prevented cardiac dysfunction in patients
with essential hypertension [34]. This decrease in the car-
diac damage markers in the diabetic rats upon AZL treat-
ment supported the hypothesis that AZL reduce the risk
of metabolic disorders associated with diabetic. Further-
more, there was no change in serum markers of liver
function in AZL treated group compared with untreated
diabetic rats, which suggests that AZL treatment did not
cause any xenobiotic side effects during the study.
Apart from the altered metabolic condition, diabetes is
also an inflammation-prone condition. Hyperglycemia-
induced ROS stimulates signal transduction to instigate
inflammatory cytokines, e.g. TNF-a,I F N - g and TGF-b
[61]. This leads to systemic inflammation, cardiac dys-
function and exacerbates the severity of diabetes [62]. In
the present study, AZL-treated diabetic rats showed
effective suppression of these pro-inflammatory cyto-
kines. These results strongly indicate that AZL is a
potential agent against diabetes-associated systemic
inflammation. We also noticed that AZL increased the
levels of the anti-inflammatory and immunosuppressive
cytokine IL-4 but did not affect the levels of IL-10.
Thus, the resulting reduction in the inflammation in the
AZL treated group was due to the stimulation of IL-4
but probably not due the production of anti-inflamma-
tory cytokine IL-10. Inhibition of circulating levels of
TNF-a,I F N - g and TGF-b and an increase in the levels
of IL-4 can explain the lowering of serum triglyceride
and total cholesterol levels, potentially mediated, at least
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metabolism in AZL-treated diabetic rats.
In our study, the altered lipid profile observed in the
diabetic condition was also abrogated by AZL treatment.
AZL improved the serum cholesterol, triglycerides, LDL
and VLDL. It also improved the markers of atherogenic
risk, (total cholesterol/HDL and LDL/HDL ratio). These
findings suggest that AZL possesses lipid lowering activ-
ities due to its unique anti-atherogenic properties which
also contribute additionally to its cardiovascular protec-
tive actions. This is the first report which evaluated the
positive effect of AZL on lipid profile in STZ-diabetic
rats Diabetes Care27Full Text.
Conclusion
In conclusion, we showed that AZL treatment abrogated
the metabolic disorders in STZ-diabetic rats at least partly
through its antioxidant and antiatherogenic properties.
These results indicate that the protective effect of AZL
might be, at least in part, due to its inhibitory ability on
free radical formation, or due to its free radical scavenging
ability. These data also indicate that AZL exerts cardiopro-
tection due to its unique modulatory and antioxidative
property and thus may be a promising ‘cardioprotective
DHP’ that can even target the secondary cardiac complica-
tion of diabetes. This property of AZL could be further
extended to clinics and can be used as adjuvant therapy in
cardiac complications especially in diabetes.
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